BMS
3Q Revenues: $11.9 billion (+8%)
3Q Earnings: $1.2 billion (-37%)
YTD Revenues: $35.96 billion (+7%)
YTD Loss: $9.0 billion (earnings were $6.3 billion 3Q23)
Comments: Growth in the quarter was primarily driven by Eliquis, partially offset by generic erosion of Sprycel due to the loss of exclusivity. Opdivo sales were up 4% to $2.4 billion in the quarter. Eliquis sales were $3.0 billion, up 11%. Revlimid sales were down 1% to $1.4 billion. Orencia sales were $936 million, up 1%. Pomalyst sales were up 3% to $898 million. Sprycel sales were down 44% to $290 million. Reblozyl sales were up 80% to $447 million. 
 
In the quarter, acquired IPRD increased to $262 million from $80 million and acquired intangible assets increased 7% to $2.4 billion, primarily due to the RayzeBio acquisition in 2024 and approval of Augtyro in the fourth quarter.